
    
      Patients with membranous nephropathy and nephrotic syndrome will be treated with ACTH for 6
      months. Proteinuria remission at 12 months will be the primary endpoint. Different biomarkers
      including anti-PLA2R autoantibodies, circulating regulatory T cells, and autoreactive memory
      B cells will be serially measured to identify predictors of response to therapy.
    
  